James Hippel compensation by year
BIO-TECHNE Summary Compensation Table · all 10 fiscal years held| Component | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Salary | $425,000 | $460,000 | $476,100 | $514,188 | $566,000 | $600,500 | $636,600 | $668,430 | $695,167 | $723,000 |
| Bonus | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Stock awards | $216,980 | $349,988 | $370,000 | $399,916 | $502,389 | $574,849 | $624,760 | $687,601 | $2,112,272 | $4,453,020 |
| Option awards | $685,875 | $1,049,814 | $1,110,007 | $1,200,090 | $1,502,483 | $2,724,928 | $1,874,812 | $2,062,485 | $2,165,618 | $907,273 |
| Non-equity incentive | $421,660 | $356,310 | $483,485 | $634,254 | $576,716 | $1,095,156 | $1,289,740 | $13,520 | $218,978 | $926,163 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| All other | $9,042 | $10,660 | $9,295 | $9,342 | $9,470 | $9,445 | $10,117 | $9,834 | $10,597 | $17,926 |
| Total | $1,758,557 | $2,226,773 | $2,448,887 | $2,757,790 | $3,157,716 | $5,004,878 | $4,436,029 | $3,441,870 | $5,202,632 | $7,027,382 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: BIO-TECHNE Corp DEF 14A filed September 19, 2025, accession 0001308179-25-000599, and prior-year filings. Open the filing on EDGAR.
How this page was built: the BIO-TECHNE Corp filed document, accession 0001308179-25-000599. Every figure is read from that document and cited to the page and table it appears in. Filed September 19, 2025.
Equity holdings
unvested awards at FY2024 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 26,318 | $1,885,685 | — |
| PSU | 12,798 | $916,977 | — |
| PSU | 10,912 | $781,845 | — |
| PSU | 7,780 | $557,437 | — |
| Option | 33,916 | — | $94.52 |
| Option | 19,148 | — | $66.97 |
| Option | 45,923 | — | $84.61 |
| Option | 20,268 | — | $120.46 |
Per the Outstanding Equity Awards at Fiscal Year-End table in BIO-TECHNE Corp's FY2024 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
33 Form 4 lines since the FY2025 proxy (filed September 19, 2025)current to 2026-11-10 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-11-01 | Exercise or conversion | — | 11,545 | $0.00 | 181,816 |
| 2026-11-01 | Tax withholding | — | 5,096 | $72.66 | 176,720 |
| 2026-11-01 | Exercise or conversion derivative | — | 11,545 | $0.00 | 11,544 |
| 2026-08-17 | Grant or award derivative | — | 36,459 | $0.00 | 36,459 |
| 2026-08-17 | Grant or award derivative | — | 22,438 | $0.00 | 22,438 |
| 2026-08-15 | Tax withholding | — | 4,423 | $72.40 | 170,271 |
| 2026-08-15 | Exercise or conversion | — | 9,980 | $0.00 | 174,694 |
| 2026-08-15 | Disposition to the issuer derivative | — | 34,982 | $0.00 | 2,332 |
The 8 most recent of 33 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
BIO-TECHNE’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Kim Kelderman | President and CEO | $8,151,181 |
| James Hippel · this page | Executive Vice President and CFO | $7,027,382 |
| William Geist | President, Protein Sciences | $3,139,299 |
| Matthew McManus | President, Diagnostics and Spatial Biology | $2,846,619 |
| Shane Bohnen | Senior Vice President and General Counsel | $1,980,732 |
James Hippel's compensation dossier, BIO-TECHNE
You have read James Hippel's totals and holdings. The dossier adds each equity grant BIO-TECHNE disclosed for James Hippel and BIO-TECHNE's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.
See an example →The full BIO-TECHNE compensation record
free company briefThis page is one person within BIO-TECHNE's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the BIO-TECHNE proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order BIO-TECHNE's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are BIO-TECHNE's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order TECH
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.